Stockscreener 앱 받기
0.69
0.94%
0.0064
전일 마감가:
$0.6836
열려 있는:
$0.6952
하루 거래량:
695.73K
Relative Volume:
0.62
시가총액:
$47.59M
수익:
$3.67M
순이익/손실:
$-13.83M
주가수익비율:
-2.4643
EPS:
-0.28
순현금흐름:
$-10.79M
1주 성능:
-4.41%
1개월 성능:
-2.82%
6개월 성능:
-31.34%
1년 성능:
-16.77%
1일 변동 폭
$0.6801
$0.7342
1주일 범위
$0.67
$0.7342
52주 변동 폭
$0.59
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
ICCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
0.6901 | 46.82M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
125.02 | 218.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.47 | 144.86B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.44 | 139.34B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
102.02 | 130.75B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.72 | 49.78B | 5.88B | 1.34B | 799.60M | 2.3489 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
Icecure Receives Notice of Patent Allowance in China for A Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - marketscreener.com
IceCure Medical (ICCM) Secures Patent Approval in China for Cryo - GuruFocus
IceCure Medical Secures Patent in China for Cryogen Flow Control - TipRanks
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - PR Newswire
Why IceCure Medical Ltd stock remains on buy listsJuly 2025 Movers & Real-Time Volume Analysis Alerts - Newser
How IceCure Medical Ltd stock benefits from global expansionJuly 2025 Analyst Calls & Free Accurate Trade Setup Notifications - Newser
IceCure Medical schedules special shareholder meeting for January 2026 By Investing.com - Investing.com Canada
IceCure Medical schedules special shareholder meeting for January 2026 - Investing.com
IceCure Medical Announces Special General Meeting for Key Votes - TipRanks
Why retail investors pile into IceCure Medical Ltd stockJuly 2025 Catalysts & Short-Term Swing Trade Alerts - BỘ NỘI VỤ
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances (PR Newswire) - Aktiellt
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period (PR Newswire) - Aktiellt
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2025 Earnings Call Transcript - Insider Monkey
How IceCure Medical Ltd stock compares to market leadersJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Is IceCure Medical Ltd stock a bargain at current levels2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com
IceCure Medical Reports Q3 2025 Financial Results - TipRanks
Is IceCure Medical Ltd a candidate for recovery playJuly 2025 Sentiment & Fast Gain Swing Trade Alerts - newser.com
IceCure Medical Ltd stock momentum explained2025 Year in Review & Verified Stock Trade Ideas - newser.com
Using Ichimoku Cloud for IceCure Medical Ltd technicals - newser.com
IceCure Medical’s Earnings Call Highlights Growth Potential - TipRanks
ICCM: FDA approval of ProSense drives growth prospects amid revenue decline and strong cash position - TradingView
Does IceCure Medical Ltd fit your quant trading modelJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
IceCure Medical Q3 2025 Earnings Call Transcript - MarketBeat
IceCure Medical Gains FDA Approval for ProSense® in Breast Cancer Treatment - MSN
IceCure Medical Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025 - marketscreener.com
IceCure Medical Ltd. (ICCM) Q3 FY2025 earnings call transcript - Yahoo Finance
ICCM: FDA approval for ProSense® sets stage for accelerated growth despite lower 2025 revenue - TradingView
When is the best time to exit IceCure Medical LtdTrade Analysis Report & Fast Gain Stock Trading Tips - newser.com
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - Eastern Progress
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 - Finviz
IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - Finviz
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - The Malaysian Reserve
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Report Preview: What To Expect - GuruFocus
IceCure's ProSense® cryoablation system receives regulatory approval in Switzerland for indications including breast, lung, liver, and kidney cancer - MarketScreener
IceCure Medical receives Nasdaq minimum bid price notification - Medical Buyer
Why IceCure Medical Ltd stock attracts high net worth investors2025 Stock Rankings & Expert Curated Trade Ideas - newser.com
Market reaction to IceCure Medical Ltd’s recent newsRecession Risk & Scalable Portfolio Growth Ideas - newser.com
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price No - GuruFocus
IceCure Medical Receives Nasdaq Bid Price Notification - TipRanks
IceCure Medical announces receipt of Nasdaq minimum bid price notification - MarketScreener
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.17%
1.69%
자본화:
|
볼륨(24시간):